Wockhardt Limited (IN:WOCKPHARMA)
:WOCKPHARMA
WOCKPHARMA Stock Chart & Stats
₹1405.55
-₹25.55(-1.72%)
At close: 4:00 PM EST
₹1405.55
-₹25.55(-1.72%)
Day’s Range― - ―
52-Week Range₹1,086.80 - ₹1,870.00
Previous CloseN/A
Volume236.67K
Average Volume (3M)24.00K
Market Cap
₹219.06B
Enterprise Value₹241.55B
Total Cash (Recent Filing)₹9.30B
Total Debt (Recent Filing)₹24.56B
Price to Earnings (P/E)100.2
Beta1.52
Next Earnings
Jun 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.63
Shares Outstanding162,485,570
10 Day Avg. Volume15,364
30 Day Avg. Volume24,000
Financial Highlights & Ratios
PEG Ratio5.29
Price to Book (P/B)5.18
Price to Sales (P/S)7.42
P/FCF Ratio-85.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Gross Profit MarginA material rise in gross margin indicates better cost control or a favorable product mix at the core manufacturing level. Sustained higher gross margins provide a structural buffer to absorb pricing pressure, support incremental investment in capacity or R&D, and improve long-term profitability potential if operating leverage is realized.
Lower Leverage & Stable Capital StructureMeaningfully reduced leverage and a majority equity ratio strengthen financial flexibility. Lower debt servicing needs reduce insolvency risk and make it easier to fund capex, regulatory compliance or strategic initiatives with internal cash or modest external financing, improving resilience over the medium term.
Diversified Formulations And API BusinessA business spanning finished dosages and API production across domestic and export markets creates diversified revenue streams and vertical integration benefits. This structural mix supports revenue stability, cross‑market scale, and opportunities to capture higher value by supplying both internal and external customers over multiple therapeutic areas.
Bears Say
Persistent Net LossesSustained net losses erode retained earnings and limit the company's ability to self‑fund growth or return capital. Over several quarters this weakens investor confidence, constrains strategic choices, and requires either consistent operational turnarounds or external financing to restore profitability and rebuild equity.
Negative Operating And Free Cash FlowNegative operating and free cash flow indicate the core business is not currently generating surplus cash to fund capex or debt service. This structural cash deficit forces reliance on external financing, limiting strategic agility, and raises vulnerability to interest rate or liquidity shocks over the coming months.
Weak EBIT/EBITDA Margins And Negative ROEContinuing weak operating margins and negative ROE signal limited profitability after operating costs and poor capital efficiency. This restricts the company's ability to scale profitably, invest in higher‑margin products or commercialization, and lengthens the timeline required to achieve sustainable shareholder returns.
Wockhardt Limited News
WOCKPHARMA FAQ
What was Wockhardt Limited’s price range in the past 12 months?
Wockhardt Limited lowest stock price was ₹1086.80 and its highest was ₹1870.00 in the past 12 months.
What is Wockhardt Limited’s market cap?
Wockhardt Limited’s market cap is ₹219.06B.
When is Wockhardt Limited’s upcoming earnings report date?
Wockhardt Limited’s upcoming earnings report date is Jun 03, 2026 which is in 55 days.
How were Wockhardt Limited’s earnings last quarter?
Wockhardt Limited released its earnings results on Feb 10, 2026. The company reported ₹3.631 earnings per share for the quarter, beating the consensus estimate of N/A by ₹3.631.
Is Wockhardt Limited overvalued?
According to Wall Street analysts Wockhardt Limited’s price is currently Overvalued.
Does Wockhardt Limited pay dividends?
Wockhardt Limited pays a Notavailable dividend of ₹9.218 which represents an annual dividend yield of N/A. See more information on Wockhardt Limited dividends here
What is Wockhardt Limited’s EPS estimate?
Wockhardt Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Wockhardt Limited have?
Wockhardt Limited has 162,485,570 shares outstanding.
What happened to Wockhardt Limited’s price movement after its last earnings report?
Wockhardt Limited reported an EPS of ₹3.631 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.086%.
Which hedge fund is a major shareholder of Wockhardt Limited?
Currently, no hedge funds are holding shares in IN:WOCKPHARMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Wockhardt Limited
Wockhardt Limited, a pharmaceutical and biotechnology company, manufactures and markets active pharmaceutical ingredients, formulations, bio-similars, and vaccines in India, the United States, the United Kingdom, Ireland, Mexico, Russia, and internationally. It develops various molecules primarily in the areas of infectious diseases, such as WCK 5222, WCK 4282, WCK 4873, WCK 771 and WCK 2349, and WCK 6777 molecules. The company's biopharmaceutical products include Glaritus, an insulin analog; Wosulin, an r-DNA insulin; Wepox, a recombinant erythropoietin that is used in the treatment of anemia caused by cancer and chronic renal failure; and Biovac-B, a hepatitis B vaccine. It also provides contract manufacturing services for sterile injectables, lyophilization, and other dosage forms; and research services. The company was founded in 1967 and is headquartered in Mumbai, India. Wockhardt Limited is a subsidiary of Themisto Trustee Company Private Limited.
Technical Analysis
Alkem Laboratories Ltd.
―
Aurobindo Pharma Ltd
―
Dr. Reddy's Laboratories Ltd.
―
Glenmark Pharmaceuticals Limited
―
IPCA Laboratories Limited
―